FRI0184 Dendritic Cells as a Potential Object in Cellular Immunotherapy in Rheumatoid Arthritis
Authors: S.A. Falaleeva, V.V. Kurilin, N.S. Shkaruba, O.A. Chumasova, A.E. Sizikov, S.V. Sennikov
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Since dendritic cells (DC) are involved in the development of autoimmune inflammation, DC are considered to be target cells for specific therapy of rheumatoid arthritis (RA)[1]. The development of treatment strategies requires comprehensive research into the qualitative characteristics of DC subtypes both ex vivo from RA patients and in vitro, to determine the possibility of inducing functionally mature DC in RA. <h3>Objectives</h3> To study different subpopulations of DC from peripheral blood and to induce simular DC in culture <h3>Methods</h3> To generate different subsets of DC we used rhIL-3 (BioVision, USA), R848 (Resiquimod, BioVision, USA), LPS (25 ng/ml, E. coli O114:B4; Sigma, USA), rhGM-CSF and rhIL-4 (PeproTech, USA). Phenotypic characterization of immature mDC(Lin-HLADR+CD123-CD11c+) and pDC(Lin-HLA-DR+CD123+CD11c-) in the was estimated by the positive expression of CD80, CD83, CCR7, IL-10, IL-12, IFN-α. Analysis of the DC target populations contents was performed using flow cytometer "BD FACSVerse". <h3>Results</h3> DC from RA patients were characterized by low expression levels of CD80 and CD83 on both populations cells and high expression of CCR7 only on pDC. An increase in mDC and pDC producing IL-12 and IFN-α and a decrease in mDC and pDC producing IL-4 and IL-10 were shown in RA. Immature DC (iDC), similar to mDC in terms of their phenotypic characteristics, and mature mDC were generated and expression of surface markers was analyzed. DC induced according to this protocol expressed CD80, CD83 and CCR7 at similar levels for all groups at each stage of maturation analysis. Healthy donors (HD) DC had increased expression of CD80 in response to TNF-α stimulation, while mDC from RA patients had significantly increased expression of both CD80 and CD83. The expression levels of CCR7 on immature mDC was very low for both HD and RA patients, and increased upon addition of TNF-α. Analysis of DC cytokine-producing activity demonstrated that induced mature DC produced cytokines upon addition of specific stimulators, but cells from RA patients showed no significant differences in IL-10, IL-12, and IFN-α production compared with HD. iDC with plasmacytoid phenotypic characteristics and mature pDC were generated and the expression of surface markers was analyzed. Using IL-3, R848, and LPS as stimulating factors significantly increased the expression levels of CD80 and CD83 after maturation in RA and HD groups. Additionally, the DC maturation process was accompanied by a simultaneous increase in CCR7 expression when pDC from RA patients or HD were stimulated by LPS. The expression levels of CD80, CD83 and CCR7 did not differ significantly between RA patients and HD at all stages of pDC maturation. We observed no differences in terms of IL-10 and IL-12 production by mature pDC between the RA and HD groups. However, pDC from RA patients demonstrated significantly higher production of IFN-α compared with pDC from HD. <h3>Conclusions</h3> In summary, the current study indicated DC might be target cells for the therapy of rheumatoid arthritis. Additionally, the data on the in vitro induction of functionally competent DC suggest they could be used to develop cell-based methods for RA therapy. <h3>References</h3> Lutzky V, Hannawi S, Thomas R. Cells of the synovium in rheumatoid arthritis. Dendritic cells. Arthritis Res Ther 2007;9:219. <h3>Disclosure of Interest</h3> None declared